文献速递造血干细胞移植与细胞治疗贫血与红细胞疾病

单倍型造血干细胞移植联合无关脐血单位治疗127例获得性重型再生障碍性贫血的结局

[Outcome of combination of HLA-haploidentical hematopoietic SCT with an unrelated cord blood unit for 127 patients with acquired severe aplastic anemia].
PubMed 文献 · Zhonghua Xue Ye Xue Za Zhi · 2018-01-01

回顾性分析2011年9月至2017年4月接受单倍型造血干细胞移植联合第三方脐血移植的127例重型再生障碍性贫血患者,其中极重型65例,中位年龄23.5岁。121例成功植入,4年总生存率(78.5±4.3)%,无失败生存率(77.4±4.3)%。结论认为该方案在无全相合供者时为可行选择。

要点

  • 121例存活患者均获单倍型植入,中性粒细胞和血小板中位植入时间分别为11天和15天。
  • Ⅱ~Ⅳ度急性GVHD发生率24.79%(30/121),中/重度慢性GVHD发生率14.15%(15/106)。
  • 4年预期总生存率(78.5±4.3)%,无失败生存率(77.4±4.3)%。

核心结论

  • 单倍型造血干细胞移植联合第三方脐血治疗重型再生障碍性贫血疗效确切且安全性较好。
  • 在无全相合供者情况下可作为有价值的治疗选择。

研究设计与样本

  • 回顾性分析2011年9月至2017年4月接受单倍型造血干细胞移植联合无关脐血单位移植的127例重型再生障碍性贫血患者。
  • 患者中男74例、女53例,极重型65例,中位年龄23.5(3~54)岁,诊断至移植中位时间2(0.5~180)个月。
  • 预处理为改良Bu/Cy+ATG/ALG方案,GVHD预防为环孢素A、霉酚酸酯联合短程甲氨蝶呤。
  • 脐血选用单份、HLA配型≥4/6相合者。

主要发现

  • 回输单倍型供者单个核细胞10.87(3.61~24.00)×10^8/kg,CD34+细胞3.49(1.02~8.89)×10^6/kg;脐血单个核细胞2.22(1.10~7.30)×10^7/kg,CD34+细胞0.56(0.16~2.27)×10^5/kg。
  • 127例中5例早期死亡,可评估122例中1例原发植入失败,其余121例均获单倍型植入。
  • 中性粒细胞、血小板植入中位时间分别为11(9~28)天、15(9~330)天,5例发生血小板植入不良,感染发生率58.27%(74/127)。
  • 中位随访20.5(4~60)个月,Ⅱ~Ⅳ度急性GVHD发生率24.79%(30/121),中/重度慢性GVHD发生率14.15%(15/106)。
  • 4年预期总生存率(78.5±4.3)%,无失败生存率(77.4±4.3)%。

临床怎么用

  • 作者认为,在无全相合供者情况下,单倍型造血干细胞移植联合第三方脐血干细胞移植可作为有价值的治疗选择。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To evaluate the outcome of combination of haploidentical donor (HID) hematopoietic stem cell transplantation (HSCT) with an unrelated cord blood unit for severe aplastic anemia (SAA). Methods: The clinical data of 127 SAA patients [including 74 male and 53 female patients, 65 very severe aplastic anemia (vSAA), the median age as 23.5(3-54) years] received HID-HSCT from September 2011 to April 2017 were analyzed retrospectively. The median interval from SAA diagnosis to transplantation was 2 (0.5-180) months. The conditioning was modified Bu/Cy+ATG/ALG-based (Busulfan + cyclophosphamide + antithymocyte immunoglobulin/antilymphocyte immunoglobulin) regimen. Cord blood units were selected based on the results of HLA typing and cell doses evaluated before freezing. Units with at least 4/6 matched HLA loci became the candidates. Prophylaxis for graft-versus host disease (GVHD) was by cyclosporine (CsA), mycophenolate mofetil (MMF) plus short-term methotrexate (MTX). Results: The median values of absolute nucleated cell counts were 10.87 (3.61-24.00)×10(8)/kg in the haploidentical grafts and 2.22 (1.10-7.30)×10(7)/kg in the cord blood units, respectively. The median doses of CD34(+) cells infused were 3.49(1.02-8.89) ×10(6)/kg in the haploidentical grafts and 0.56 (0.16-2.27) ×10(5)/kg in the cord blood units, respectively. Of the 127 patients, 5 patients occurred early death, one patient occurred primary graft failure. All 121 surviving patients attained complete haploidentical engraftment. The median durations of myeloid engraftment were 11 (9-28) days and 15 (9-330) days for platelets, with a cumulative platelet engraftment incidence of 96.1%. The incidence of infection was 58.27% (74/127). During a median follow-up of 20.5 (4-60) months, the incidence of grade Ⅱ-Ⅳ acute GVHD was 24.79% (30/121), moderate-severe chronic GVHD was 14.15% (15/106), 4-year estimated overall survival was (78.5±4.3) %, 4-year estimated failure-free survival was (77.4±4.3) %, respectively. Conclusion: Combination of HID-HSCT and an unrelated umbilical cord blood unit was a feasible choice with favorable outcome for SAA patients without matched donors. 目的: 评价单倍型造血干细胞移植(haplo-HSCT)联合第三方脐血干细胞移植治疗重型再生障碍性贫血(SAA)的疗效及安全性。 方法: 对2011年9月至2017年4月间接受haplo-HSCT联合第三方脐血干细胞移植的127例SAA患者进行回顾性研究。 结果: 全部127例SAA患者中,男74例,女53例,中位年龄23.5(3~54)岁,其中极重型再生障碍性贫血65例。诊断至移植中位时间2(0.5~180)个月。单倍型造血干细胞来源为骨髓+外周血。脐血均选用单份,HLA配型≥4/6相合。127例患者均接受改良Bu/Cy+ATG/ALG预处理方案(白消安+环磷酰胺+抗胸腺细胞球蛋白/抗淋巴细胞球蛋白)。以环孢素A、霉酚酸酯联合短程甲氨蝶呤预防GVHD。回输单倍型供者单个核细胞10.87(3.61~24.00)×10(8)/kg,CD34(+)细胞3.49(1.02~8.89)×10(6)/kg;回输脐血单个核细胞2.22(1.10~7.30)×10(7)/kg,CD34(+)细胞0.56(0.16~2.27)×10(5)/kg。127例患者中5例发生早期死亡。在可评估的122例患者中,1例发生原发植入失败,其余121例患者成功植入(均为单倍型造血干细胞植入)。中性粒细胞、血小板植入时间分别为11(9~28)d、15(9~330)d,5例患者发生血小板植入不良。移植过程中74例(58.27%)发生感染。存活患者中位随访20.5(4.0~60.0)个月,Ⅱ~Ⅳ度急性GVHD发生率为24.79%(30/121),中/重度慢性GVHD发生率为14.15%(15/106),预期4年总生存率为(78.5±4.3)%,无失败生存率为(77.4±4.3)%。 结论: haplo-HSCT联合第三方脐血干细胞移植治疗SAA疗效确切且安全性较好,在无全相合供者情况下可作为有价值的治疗选择。.

来源:Zhonghua Xue Ye Xue Za Zhi,查看原文。版权归原作者所有。

引用

  1. Liu LM, Zhang YM, Zhou HF, et al. [Outcome of combination of HLA-haploidentical hematopoietic SCT with an unrelated cord blood unit for 127 patients with acquired severe aplastic anemia]. Zhonghua Xue Ye Xue Za Zhi. 2018. PMID: 30180460. doi:10.3760/cma.j.issn.0253-2727.2018.08.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。